共 50 条
- [21] MM-111, a bispecific HER2 and HER3 antibody, inhibits trastuzumab-resistant tumor cell growthCANCER RESEARCH, 2012, 72Zhang, BoStephanie NguyenHuhalov, AlexandraNielsen, Ulrik B.Niyikiza, CletMcDonagh, Charlotte F.Kudia, Arthur J.Onsum, Matthew
- [22] Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and PlasticityCLINICAL CANCER RESEARCH, 2015, 21 (18) : 4110 - 4122Jacobsen, Helle J.Poulsen, Thomas T.Dahlman, AnnaKjaer, IdaKoefoed, KlausSen, Jette W.Weilguny, DietmarBjerregaard, BoletteAndersen, Christina R.Horak, Ivan D.Pedersen, Mikkel W.Kragh, MichaelLantto, Johan
- [23] Triple negative breast cancer is vulnerable to Pan-HER, an antibody mixture simultaneously targeting EGFR, HER2 and HER3CANCER RESEARCH, 2016, 76Choi, D. S.Qian, W.Davila-Gonzalez, D.Ensor, J. E.Lantto, J.Kragh, M.Horak, I. D.Chang, J. C.
- [24] Zenocutuzumab is an effective HER2/HER3 Biclonics® antibody in cancers with NRG1 fusionsMOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)Gerlach, JanOdintsov, IgorSchackmann, RonLadanyi, Marcvan Bueren, Jeroen LammertsSomwar, RomelGeuijen, Cecile
- [25] A PHASE 1 STUDY OF MM-111; A BISPECIFIC HER2/HER3 ANTIBODY FUSION PROTEIN, COMBINED WITH MULTIPLE TREATMENT REGIMENS IN PATIENTS WITH ADVANCED HER2 POSITIVE SOLID TUMORSANNALS OF ONCOLOGY, 2012, 23 : 170 - 170Richards, D.Braiteh, F.Anthony, S.Edenfield, W.Hellerstedt, B.Raju, R.Conkling, P.McDonagh, C.Frye, S.Moyo, V.
- [26] Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumabJournal of Gastroenterology, 2015, 50 : 467 - 479Toru KawamotoKazunori IshigeMelanie ThomasYoriko Yamashita-KashimaSei ShuNobuyuki IshikuraShunichi AriizumiMasakazu YamamotoKunihiko KurosakiJunichi Shoda
- [27] Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumabJOURNAL OF GASTROENTEROLOGY, 2015, 50 (04) : 467 - 479Kawamoto, ToruIshige, KazunoriThomas, MelanieYamashita-Kashima, YorikoShu, SeiIshikura, NobuyukiAriizumi, ShunichiYamamoto, MasakazuKurosaki, KunihikoShoda, Junichi
- [28] Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Schram, Alison M.Goto, KoichiKim, Dong-WanMartin-Romano, PatriciaOu, Sai-Hong IgnatiusO'Kane, Grainne M.O'Reilly, Eileen MaryUmemoto, KumikoDuruisseaux, MichaelNeuzillet, CindyOpdam, FransAhnert, Jordi RodonNagasaka, MisakoWeinberg, Benjamin AdamMacarulla, TeresaJoe, Andrew K.Ford, JimStalbovskaya, ViktoriyaWasserman, ErnestoDrilon, Alexander E.
- [29] Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Hamilton, Erika PaigePetit, ThierryPistilli, BarbaraGoncalves, AnthonyFerreira, Ana AlexandraDalenc, FlorenceCardoso, FatimaMita, Monica M.Dezentj, Vincent O.Manso, LuisGraff, Stephanie L.Bidard, Francois ClementAftimos, Philippe GeorgesEscriv, SantiagoAfonso, NoemiaWasserman, ErnestoBol, KeesStalbovskaya, ViktoriyaVliet, AnastasiaBachelot, Thomas
- [30] BIOMARKER ANALYSIS OF A PHASE 1 STUDY OF MM-111, A BISPECIFIC HER2/HER3 ANTIBODY FUSION PROTEIN, IN COMBINATION WITH MULTIPLE TREATMENT REGIMENS IN PATIENTS WITH ADVANCED HER2 POSITIVE SOLID TUMORSANNALS OF ONCOLOGY, 2014, 25Kudla, A.Adiwijaya, B.Paragas, V.Richards, D.Braiteh, F.Garcia, A. A.Denlinger, C. S.Conkling, P.Edenfield, W. J.Anthony, S.Hellerstedt, B.Raju, R.Becerra, C.Harb, W.Smith, D.Kawash, K.Frye, S.McDonagh, C. F.Moyo, V.